Tumor-endothelial interaction contributes to local prostate tumor growth and distant metastasis. In this communication, we designed a novel approach to target both cancer cells and their ''crosstalk'' with surrounding microvascular endothelium in an experimental hormone refractory human prostate cancer model. We evaluated the in vitro and in vivo synergistic and/or additive effects of a combination of conditional oncolytic adenovirus plus an adenoviral-mediated antiangiogenic therapy. In the in vitro study, we demonstrated that human umbilical vein endothelial cells (HUVEC) and human C4-2 androgen-independent (AI) prostate cancer cells, when infected with an antiangiogenic adenoviral (Ad)-Flk1-Fc vector secreting a soluble form of Flk1, showed dramatically inhibited proliferation, migration and tubular formation of HUVEC endothelial cells. C4-2 cells showed maximal growth inhibition when coinfected with Ad-Flk1-Fc and Ad-hOC-E1, a conditional replication-competent Ad vector with viral replication driven by a human osteocalcin (hOC) promoter targeting both prostate cancer epithelial and stromal cells. Using a threedimensional (3D) coculture model, we found that targeting C4-2 cells with Ad-hOC-E1 markedly decreased tubular formation in HUVEC, as visualized by confocal microscopy. In a subcutaneous C4-2 tumor xenograft model, tumor volume was decreased by 40-60% in animals treated with Ad-Flk1-Fc or Ad-hOC-E1 plus vitamin D 3 alone and by 90% in a combined treatment group, compared to untreated animals in an 8-week treatment period. Moreover, three of 10 (30%) pre-established tumors completely regressed when animals received combination therapy. Cotargeting tumor and tumor endothelium could be a promising gene therapy strategy for the treatment of both localized and metastatic human prostate cancer.
H ormone-refractory prostate cancer is one of the leading causes of cancer mortality and morbidity in North American men. 1 Despite aggressive efforts toward earlier detection and treatment, the mortality resulting from distant metastasis of prostate cancer remains high. The most common site of prostate cancer metastasis is bone, with skeletal metastases identified at the time of autopsy up to 90% in patients dying from prostate cancer. 2, 3 While localized prostate cancer may be cured, patients with advanced hormone refractory and bone metastatic cancer have a poor prognosis and a median survival time of 4 months. 4, 5 Conventional therapies such as hormone therapy, radiation therapy and chemotherapy assume that cancer is a clonal cell disease and that targeting tumor epithelium can best control tumor growth. These forms of therapy are highly effective but unfortunately not longlasting. Patients eventually develop hormone-refractory disease resistant to conventional therapeutic interventions. New therapeutic approaches to hormone-refractory prostate cancer are urgently needed.
The growth and metastasis of prostate cancer cells are intimately affected by their microenvironment. Wellestablished autocrine, paracrine and endocrine communication loops exist between cancer cells and their adjacent cellular components, 6 including (1) smooth muscle cells and fibroblasts, which provide critical soluble growth factors and extracellular matrices (ECMs) that support tumor growth, survival and differentiation; (2) endothelial cells, which form critical blood vessels, supply oxygen and nutrients to the tumor epithelium, and remove metabolic wastes from the tumor cells; (3) inflammatory cells, which could support important cytokines to defend against bacterial infection of the tumor epithelium and also potentially maintain the growth requirements of tumor cells. Using an experimental coculture cell model and chimeric tumor model 7 comprised of human prostate cancer and bone stromal cells to mimic a functional prostate organoid, our laboratory designed a strategy cotargeting both tumor and its supporting stroma. Recent studies with bone and directed targeting of hormone refractory prostate cancer using a combination of chemotherapy (which targets prostate tumor epithelium) plus strontium 89 (which targets bone), and in an experimental model of prostate cancer skeletal metastasis using a cotargeting strategy with conditional replication-competent adenoviral vector in which viral replication in both tumor and stromal cells was controlled by a tissue-specific and tumor restrictive promoter, osteocalcin (OC), has shown great promise, substantially improving patient survival 5 and curing animals with pre-existing prostate tumor in the skeleton. 8 These findings suggest that a cotargeting strategy could ultimately improve the treatment of hormone-refractory human prostate cancer and bone metastasis.
Extensive studies by many investigators have established the central role of tumor-associated angiogenesis in the invasion, growth and metastasis of solid tumors. 9 Tumor-associated angiogenesis can be effectively targeted as an anticancer therapeutic strategy. [10] [11] [12] Tumor cell behaviors can be greatly influenced by the balance of surrounding angiogenic stimulators and inhibitors 13 through paracrine-mediated regulation. Thus, antiangiogenic therapy can be used to try to stop new vessels from forming around a tumor and break up the existing network of abnormal capillaries feeding the cancerous mass. 14 One such approach could be to target the upregulated surface receptors on tumor endothelial cells. 15 Among these receptors, the vascular endothelial growth factor receptor 2 (VEGFR2, also known as Flk1) that binds the five isoforms of VEGF has a more restricted expression on endothelial cells and is upregulated in the tumor vasculature once these cells proliferate during neoangiogenesis. 16 Flk1 has been the subject of numerous studies in both animal models and in clinical trials. [17] [18] [19] Unfortunately, the clinical efficacy of single-agent antiangiogenic therapy has been disappointing.
To advance the cotargeting of both tumor and tumor microenvironment, we evaluated the responsiveness of prostate cancer to conditional replication-competent and VEGF receptor-based antiangiogenic therapy targeting three cell components: prostate tumor cells, prostate and bone stromal cells, and neovascular endothelial cells, in both cell culture and an experimental animal model. Our data demonstrated that adenovirus-meditated Flk1-Fc fusion protein delivery effectively suppress angiogenesis and tumor growth through a blockage of autocrine and/or paracrine mechanisms. Targeting prostate cancer cells with combined conditional oncolytic adenoviruses and antiangiogenic adenoviruses successfully achieved synergistic antitumor effects in human prostate cancer models, as described below.
Materials and methods

Cell lines and cultures
C4-2, an AI metastatic human prostate cancer cell line derived from LNCaP, 20 was grown in T medium (Invitrogen, CA) with 5% fetal bovine serum (FBS). HUVEC, a human umbilical vein endothelial cell line, was obtained from Cambrex Bio Science (Cambrex, CA) and maintained in endothelium-specific medium (EGM-2, Cambrex) according to the manufacturer's instructions. The cells were fed three times per week with fresh growth medium and maintained at 371C in 5% CO 2 .
A three-dimensional (3D) coculture system was established to assess the effect of prostate cancer cells on endothelial tubular formation. A GFP-tagged C4-2 cell line (C4-2-GFP) was generated by infection of C4-2 with a recombinant retroviruses containing enhanced green fluorescence gene (EGFP) driven by a retroviral long terminal repeat (LTR) promoter. C4-2-GFP clones were obtained after selection of the transduced C4-2 cells by G418 (0.8 mg/ml). HUVEC cells were labeled with a redfluorescent lipid dye, 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate (DiI), according to the manufacturer's instructions (Molecular Probes, OR). DiI-labeled HUVEC cells (5 Â 10 4 cells/well) were plated on chamber slides, which were precoated with Matrigel (Becton-Dickinson, NJ). The Matrigel used in this experiment was diluted 1:1 in T-medium. Cells were allowed to settle for 1 hour and then the medium was carefully aspirated and replaced with 50 ml of Matrigel. After polymerization (about 40 minutes), an overlay Matrigel containing 5 Â 10 4 C4-2/GFP cells preinfected with Ad-hOC-E1 or Ad-CMV-pA was added. Cell cultures were grown in EGM-2 plus T-medium with a ratio of 1:1 for 3 days.
Adenoviral vectors
Ad-Flk1-Fc, an adenoviral (Ad) vector containing murine Flk1-Fc signal peptide followed by the ectodomain of murine Flk1 fused to the Fc fragment of murine IgG2a, and Ad-Fc carrying only the Fc fragment 21 were constructed by Dr Calvin Kuo at Stanford University (Stanford, CA). Replication-competent Ad-hOC-E1 and its replication-defective control Ad-CMV-pA were constructed by our laboratory as described previously. 22 All of the Ad vectors were amplified and purified according to the method of Graham and Prevec. 23 Viral titer was determined by plaque assay.
Preparation of conditioned medium 1 Â 10 6 C4-2 and HUVEC cells were seeded in 60-mm culture dishes overnight and then subjected to infection with PBS (mock injection), or 10 MOI of Ad-Flk1-Fc or Ad-Fc. After 2 hours absorption, the viruses were removed and cells were cultured in fresh medium. After 48 hours culture, the conditioned media (CM) of HUVEC and C4-2 cells were harvested and concentrated by ultrafiltration with a Centricon YA10 (Millipore, MA). The amount of protein in CM was determined by BCA Protein Assay kit (Pierce, IL) and then stored at À801C until use.
Western blot
A measure of 20 mg of protein from CM or 2 ml of mouse plasma was used for immunoblotting by the NOVEX (Invitrogen, CA) system. Membrane was probed with a 1:5000 dilution of horseradish peroxidase-conjugated goat anti-murine IgG2a Fc antibody (Southern Biotech, AL). Immunoreactive bands were revealed by the enhanced chemiluminescent (ECL) plus system (Amersham, NJ) according to the manufacturer's instructions and quantified using Quantity one-4.1.1 Del Doc gel documentation software (Bio-Rad, CA).
Cell proliferation and cytotoxicity assay
The HUVEC cell proliferation assay was performed using the MTT method. Briefly, 4000 HUVEC cells were seeded overnight on 96-well plates with EGM-2 medium containing 10 ng/ml VEGF. Cells were subjected to infection with either Ad-Flk1-Fc or Ad-Fc at an MOI of 10, or incubation with 10 mg of protein obtained from a concentrated CM of Ad-infected C4-2 cells for a period of 3 days followed by MTT assay. For the in vitro cytotoxicity assay, 5 Â 10 5 C4-2 cells were seeded overnight on a 24-well plate and then infected with 10 MOI of Ad-Flk1-Fc or Ad-Fc, and 2 MOI of Ad-hOC-E1 or Ad-CMV-pA alone or combination. After 2 hours absorption, the virus-containing medium was replaced with fresh growth medium for an additional 3 days of culture. The relative cell number was assessed by optical density (OD) at 590 nm after crystal violet staining.
Tubular formation assay
Tubular formation on Matrigel was assayed as described previously 24 with a minor modification. Briefly, the 24-well plates were coated with 200 ml Matrigel. HUVEC was trypsinized, washed and resuspended in EGM-2 medium in the presence or absence of CM (10 mg/ml) from Adinfected C4-2 cells. Cells (25,000 cells/100 ml) were dispensed into each well and incubated for 8 hours. Each well was photographed under phase-contrast microscopy at Â 40 magnification. The tubular formation was quantified by counting the number of connecting branches between discrete endothelial cells.
Tubular structures generated in 3D coculture were grown on chamber slides as described above and analyzed by LSM 510 META laser scanning confocal microscopy (Carl Zeiss, NY). Images of serial optical sections were taken at 1 mm thickness in a basal-to-apical direction using a Â 10 Neofluor objective.
Cell migration assay
HUVEC cell migration was performed using the wound healing method. 25 Briefly, a confluent monolayer of HUVEC cells grown on 24-well plates was wounded using a sterile 200-ml plastic pipette tip. Displaced cells were removed with three washes, and fresh EGM-2 medium containing C4-2 CM was added. Photographs were taken under phase-contrast microscopy at 0, 12 and 24 hours after scraping. The position of the wound edge was noted against a reference grid and the migrating distance was measured using Openlab 3.0.8 software (Improvision, MA). Data were presented as the means of 10 measurements at each time point.
Animal studies
Male athymic mice (5 to 8-week old) (CD1 nu/nu) were purchased from Charles River (Wilmington, MA). The animals were kept under standard pathogen-free conditions and received care according to the criteria outlined in the National Academy of Sciences Guide for the Care and Use of Laboratory Animals. All animal experiments were approved by and complied with the regulations of Emory University School of Medicine.
Xenografts were established by subcutaneously injecting 2 Â 10 6 C4-2 cells in 100 ml Matrigel into the flanks of mice. Tumor-bearing mice were designated as small, medium and large tumor groups based on their established tumor volume of B50, B200 and B500 mm 3 , respectively. In each group, the mice were randomized and given PBS (vehicle control), 2 Â 10 9 PFU of Ad-Flk1-Fc (intratumoral injection, twice per week for 2 weeks), or 2 Â 10 9 PFU of Ad-hOC-E1 (intravenous injection for single dose) alone or together. Mice receiving Ad-hOC-E1 were treated by intraperitoneal (i.p.) administration of 100 ml vitamin D 3 (4 ng/dose) every other day for 3 weeks. Vitamin D 3 -treated mice were fed a sterilized calciumdeficient diet (ICN Research Diets) as described previously. 22 Tumor volume measurements were taken weekly and calculated according to the formula: length Â width 2 Â 0.5236. Data are expressed as fold of the end point tumor volume in treatment groups relative to that in the vehicle control group. Blood samples were also obtained from Ad-Flk1-Fc-treated mice in the small tumor group every other week by saphenous vein puncture with heparinized capillary tubes after anesthesia. All animals were killed 8 weeks after treatment. Tumors were excised and then either embedded in OTC or fixed with 10% formalin for histomorphologic and immunohistochemical analyses.
Immunohistochemistry
For microvessel density analysis, snap-frozen tissues sectioned into 4-mm specimens were fixed in cold acetone for 10 minutes, blocked with SuperBlock (Scytex Laboratories, UT) for 20 minutes, followed by incubation with a monoclonal rat anti-mouse CD31 against mouse endothelium at a 1:200 dilution (Chemicon, CA) at room temperature for 90 minutes. Sections were sequentially incubated with the secondary antibody, Alexa 594-conjugated goat anti-rat IgG, at a 1:200 dilution (Molecular Probes, OR) at room temperature for 1 hour, and then mounted and examined under fluorescence microscopy. TUNEL assay was performed to assess apoptosis. Paraffin-embedded tumor sections were dewaxed and then subjected to cell permeabilization by 350 W microwave irradiation for 5 minutes. Both basal and Ad vector-induced DNA strand breaks were then labeled with fluorescein-conjugated nucleotides in a terminal deoxynucleotidyl transferase reaction mixture supplemented in the In situ Cell Death Detection kit (Roche, IN) at 371C for 1 hour, and subjected to reaction with anti-fluorescein-POD conjugate with diaminobenzidine according to the manufacturer's instructions. The samples were counterstained with 1% methyl green to show viable cells.
Statistical analysis
Differences between treatment groups were analyzed using Student's t-test and two-tailed distribution.
Results
Expression of soluble Flk1 on human endothelial and prostate cancer cell lines infected by Ad-Flk1-Fc
To test the antiangiogenic effect of VEGF receptor-based gene therapy in a human prostate cancer model, a replication-defective Ad vector, Ad-Flk1-Fc containing the VEGF receptor-2 (Flk1) cDNA fused with a murine IgG2a Fc fragment (Fig 1a) was used in this study. The gene transduction efficacy of Ad-Flk1-Fc in human prostate cancer cells (C4-2) and endothelial cells (HUVEC) was determined by Western blot of the secreted Flk1 protein in the CM from Ad-Flk1-Fc-infected cells. Both HUVEC and C4-2 cells effectively produced Flk1-Fc fusion protein (185 kDa) or Fc (25 kDa) protein into CM when cells were infected with 10 MOI of Ad-Flk1-Fc or control vector AdFc, respectively (Fig 1b) . The quantification of protein expression shown in Western blot demonstrated a six-fold higher susceptibility of HUVEC to Ad infection in comparison with C4-2 cells, which may be due to the higher level of CAR 26 and integrin receptor expressed on the cell surface of HUVEC cells (data not shown).
Biological effect of soluble Flk1 expression by C4-2 cells on HUVEC cell proliferation, migration and tubular formation in vitro following Ad-Flk1-Fc infection
To evaluate the autocrine and paracrine effect of Ad-Flk1-Fc on tumor vasculature, vascular endothelial cells in vitro, HUVEC proliferation, migration and tubular formation were assessed when cells were exposed to adenoviruses and/or CM from Ad-infected C4-2 cells. As shown in Figure 2a , direct infection of HUVEC with 10 MOI of AdFlk1-Fc inhibited cell proliferation by 25% compared with mock-treated cells. A massively inhibitory effect (65%) on proliferation of HUVEC was observed when cells were incubated with CM from Ad-Flk1-Fc-infected C4-2. No difference was seen among mock-treated, Ad-Fc-infected and Ad-Fc-infected C4-2 CM-treated cells. The paracrine effect of secreted Flk1 by Ad-Flk1-Fc-infected C4-2 cells on the migration of HUVEC was also determined by wound healing assay. The results demonstrated that HUVEC cells incubated with CM from C4-2 cells infected with either vehicle control (PBS) or Ad-Fc moved toward and filled in a B800-mm-wide cell-free zone in a timedependent manner. Similar effects were also seen in the presence of CM from Ad-Fc-infected C4-2, whereas CM from Ad-Flk1-Fc-infected C4-2 was able to abolish the movement of HUVEC over a 24-hour incubation period (Figs 2b, c) . In addition to proliferation and migration assays that describe the initial steps of endothelial cell activation, the ability of HUVEC cells to form tube-like structures on a Matrigel membrane in culture dishes was markedly reduced upon the addition of CM from AdFlk1-Fc but not Ad-Fc-infected C4-2 as assessed by morphogenic assay (Fig 2d) . Quantitative analysis showed that Ad-Flk1-Fc inhibited tubular formation of HUVEC by 50% in comparison with the controls (Fig 2e) .
Inhibition of prostate cancer cell growth by Ad-Flk1-Fc in vitro
Recently, a potential autocrine role for VEFG in prostate cancer was reported. 27 To evaluate whether blocking the Gene therapy cotargeting tumor and endothelium F Jin et al compared with that of mock-infected cells after 72 hours of incubation. As expected, control vectors Ad-Fc and Ad-CMV-pA barely inhibited C4-2 growth but Ad-hOC-E1 effectively replicated and lysed C4-2 cells (Po.001) when compared with mock-infected C4-2 cells. Interestingly, Ad-Flk1-Fc also suppressed cell growth significantly (Po.001). The treatment of C4-2 with Ad-Flk1-Fc and Ad-hOC-E1 together enhanced further cytotoxicity beyond that of the cells treated with either Ad-Flk1-Fc or Ad-hOC-E1 alone (Po.05). These results demonstrated that Ad-Flk1-Fc directly targeted not only angiogenesis but also prostate cancer cell growth. A potential additive effect of Ad-Flk1-Fc oncolytic Ad vector on prostate cancer cell death was therefore examined (Fig 3) .
''Bystander'' antiangiogenic effects of Ad-hOC-E1 in 3D prostate organoid in vitro
Previous studies have demonstrated an increased expression of angiogenesis-stimulating factors such as VEFG, platelet-derived growth factor and transforming growth factor in prostate carcinoma. [28] [29] [30] These results suggest that prostate cancer affects endothelial proliferation through the overexpression of these angiogenic growth factors. To determine if the stimulatory effect of prostate cancer cells on endothelial cell proliferation and tubular formation is blocked by the elimination of cancer cells, we established a 3D prostate organoid model that consists of C4-2-GFP, DiI-labeled HUVEC cells or both grown on Matrigel substratum, followed by confocal imaging. As expected, HUVEC cultured in 3D Matrigel organized into an irregularly vasculogenic-like network with a total branch extension of 8577 mm by confocal microscopy analysis (Fig 4a) . The length of network formed by HUVEC increased when HUVEC was cocultured with C4-2-GFP cells (450771 mm), demonstrating the intrinsic growth of the prostate tumors as well as their inductive role on the proliferation and tubular formation of tumor vasculature (Fig 4b) . Preinfection of C4-2-GFP cells with Ad-hOC-E1, which has been demonstrated to replicate selectively in OC-expressing but not non-OC-expressing cells, 22 showed not only a decreased growth of C4-2-GFP but also reduced network formation by HUVEC (17573.5 mm) in coculture (Fig 4c) , whereas no difference was seen in HUVEC prostate organoid with C4-2-GFP cells preinfected with vector (data not shown). Taken together, these results showed prostate cancer-induced vasculogenesis of endothelial cells for the first time, and demonstrated a ''bystander'' antiangiogenic effect of AdhOC-E1 on endothelial cells (non-OC-expressing cells) by the elimination of their supporting prostate cancer cells (OC-expressing cells).
Combination of Ad-Flk1-Fc and Ad-hOC-E1 plus vitamin D 3 markedly decreased prostate tumor growth in athymic mice
We evaluated the antitumor effect of Ad-Flk1-Fc and AdhOC-E1 plus vitamin D 3 either applied alone or in combination on the growth of subcutaneous C4-2 tumors in athymic mice. To determine whether adenovirusencoded Flk1-Fc can be efficiently expressed by preexisting prostate tumors and secreted into blood circulation over an extended period using an intratumoral gene delivery approach, we analyzed plasma samples from tumor-bearing mice that had received intratumoral injections of 2 Â 10 9 PFU of Ad-Flk1-Fc twice per week for 2 weeks. Blood samples from individual mice (Fig 5a) or harvested at different time points (Fig 5b) were analyzed. High levels of Flk1-Fc were found in the majority of mouse plasma from Ad-Flk1-Fc-treated animals at day 1 after the last administration and for more than 6 weeks thereafter. These data demonstrated that high levels of Flk1-Fc in the mouse blood circulation were achieved by adenoviral vector-mediated intratumoral gene delivery. To investigate the possible effect of tumor burden on the subsequent therapeutic response of chimeric tumors to Ad vectors, tumor-bearing mice were separated into small, medium and large size groups based on the established tumor volume (B50, B200 and B500 mm 3 , respectively prior to treatment). C4-2 tumor xenografts were treated with intratumoral Ad-Flk1-Fc and intravenous Ad-hOC-E1 either alone or together. AdhOC-E1-treated mice were given i.p. vitamin D 3 to augment the oncolytic activity of Ad-hOC-E1 according to the pre-established protocol. 22 As shown in Figure 5c , both Ad-Flk1-Fc and Ad-hOC-E1 plus vitamin D 3 alone slightly reduced C4-2 tumor growth in the large-and medium-sized tumor groups, but the change was not statistically significant (P4.05). In contrast, combination 
Inhibition of angiogenesis and induction of tumor cell apoptosis in vivo
To determine whether the reduction in tumor growth was associated with a corresponding decrease in vascular Gene therapy cotargeting tumor and endothelium F Jin et al density and enhanced apoptosis, representative tumor specimens receiving different treatments were sectioned for immunohistochemical analysis of blood vessel density (CD31) and apoptosis (TUNEL assay) at the end of treatment. C4-2 tumors from animals receiving PBS showed intense staining for CD31 (Fig 6a) , indicating the presence of extensive angiogenesis in the tumor. A significant reduction in CD31-stained vessels was demonstrated after therapy with Ad-hOC-E1 plus vitamin D 3 , but the effect was much more remarkable with Ad-Flk1-Fc, particularly when used in combination with Ad-hOC-E1 (Fig 6a) . Quantification of the results reveals a reduction in microvessel density of 20, 50 and 70% in tumors treated by Ad-hOC-E1 plus vitamin D 3 , Ad-Flk1-Fc alone, and combination therapy, respectively, in comparison with the vehicle-control mice (Fig 6b) . Furthermore, TUNEL staining of tumor sections from the different treatment groups revealed an increase in tumor specimens (Fig 6c) harvested from hosts treated with Ad-hOC-E1 plus vitamin D 3 . Likewise, tumor specimens harvested from mice treated with either AdFlk1-Fc alone or combination therapy showed a progressive increase of cells stained strongly positive by TUNEL (Figs 6b, c) . These results suggest that treatment of C4-2 tumors with Ad-hOC-E1 plus vitamin D 3 and AdFlk1-Fc together inhibited the proliferation and tubular formation of tumor-associated vasculature, and also increased apoptosis in both tumor and its vasculature compartments. The regression of implant tumor xenografts and their eventual therapeutic ''cure'' can be accounted for by the cotargeting effect of this novel therapy on both tumor cells and their associated endothelium.
Discussion
Inhibiting tumor growth by attacking the tumor vascular supply is a promising concept in cancer gene therapy. However, our results (Fig 5c) and those of others 31 have demonstrated that targeting a single-cell compartment, such as the tumor-associated vascular endothelium, may not be sufficient to generate an effective and durable response. Eventually tumor cells become resistant and refractory to such treatment and augment their antiapoptotic program. 32 We developed a novel strategy that combines tumor cell-specific targeting to eliminate heterogenous tumor cell populations, using a conditional replicating Ad-hOC-E1 Ad vector, with tumor endothelium-specific targeting that uses an Ad vector secreting a polypepetide, Flk1-Fc, to interfere with the VEGF axis. In the present study, we exploited the obvious advantages of using the conditional replication-competent adenoviruses we developed 8, 22 together with an antiangiogenic therapy developed by other investigators 21, 33 to treat primary and metastatic prostate cancer. Based on the well-established reciprocal cellular interaction between prostate cancer cells, cancer-associated stroma and tumor endothelium, this cotargeting approach has the potential to inhibit cancer growth, progression and metastasis. 6, 34 Results from our studies provide further evidence that cotargeting tumor cells along with the tumor microenvironment is more effective and yields a more durable response than targeting a single-cell compartment.
Compared to other strategies currently under clinical evaluation for the treatment of prostate cancer and its metastasis, such as the use of small molecule inhibitors or monoclonal antibodies in combination with conventional antitumor drugs (reviewed by Retter et al 32 ), our approach combined an adenovirus that targets the VEGF axis in the tumor-associated neovascular endothelium with a conditionally replicating oncolytic adenovirus plus vitamin D 3 that targets tumor epithelium. This approach has several advantages. (1) The growth of both prostate cancer and its tumor-associated endothelium is interrupted. (2) The high infection rates with Ad vectors make them ideal candidates for reaching both the tumor and its associated endothelium. (3) The selectivity of the Ad vectors targeting both the tumor and its associated endothelium will cause minimal damage to normal host tissues. We previously demonstrated that OC promotermediated oncolytic adenoviruses have a broad spectra of cell-killing activity causing lysis in PSA-producing and nonproducing prostate tumors and renal cell carcinoma, bone, and prostate stromal cells in vitro. 8, 22 Vitamin D 3 has been shown to inhibit prostate cancer growth as a single agent. 35 When combined with Ad-hOC-E1, vitamin D 3 enhanced adenoviral replication by its inductive role on hOC promoter. 22 Moreover, several experimental studies have demonstrated the direct inhibitory effect of vitamin D3 on tumor-induced angiogenesis. [36] [37] [38] An adenoviral vector bearing a soluble Flk1 receptor has been reported to have the capacity to reduce tumor burden correlated with the degree of MVD in experimental animal models. 21, 33, 39 We have taken a mechanism-based approach to demonstrate for the first time the autocrine and paracrine effect of Ad-Flk1-Fc on tumor and tumor vasculature in vitro (Figures 2 and 3 ). This potent combination caused tumor xenograft regression by ''starving'' the tumor cells, blocking tumor blood supplies while exerting a direct cell-killing effect on the tumor cells themselves (Figures 5 and 6 ).
This finding is consistent with a previous report 27 where LNCaP cells stimulated with recombinant VEGF induced DNA synthesis and recruited quiescent cells into the Sphase of the cell cycle via signaling through cell surface Flk1 receptors. Moreover, as hypothesized by other investigators, 40 ,41 the inability of replication-defective Ad-Flk1-Fc to diffuse through tissues may be complemented by acquiring the ability to multiply via the exogenous adenoviral E1 gene product provided by AdhOC-E1 within tumor cells when they are cotargeted with both of these Ad vectors. Combining Ad-hOC-E1, vitamin D 3 and Ad-Flk1-Fc therefore represents an effective therapeutic approach to prostate cancer.
To succeed, a gene therapy-based approach to the treatment of cancer must be not only effective, but also safe and practical. Unlike small molecule inhibitors or anti-VEGF monoclonal antibodies, which require prolonged administration to achieve a long-term steady-state therapeutic level of the protein, a single intravenous injection of Ad vector expressing a secretable antiangiogenic protein is sufficient to achieve a persistent level of gene products in mouse serum. 21, 33, 42 However, the downside of this strategy is that systemic gene delivery by an Ad vector could cause hepatotoxicity from the overexpression of antiangiogenic factors in hepatocytes. 43 By contrast, in our study the local intratumoral injection of Ad-Flk1-Fc achieved both local and systemic accumulations of Flk1-Fc for at least 6 weeks with adequate suppression of neovascularization in C4-2 tumors via autocrine and/or paracrine blockade, and with no evidence of organ toxicity. Consistent with the observation by other groups 43 that i.p.-delivered adenovirusmediated soluble FLT-1 caused no significant systemic cytotoxicity, our experiments support the use of Ad vectors delivering Flk-1-Fc as local therapy for regional in vivo antiangiogenic prostate cancer gene therapy.
Toxicity studies of the systemic delivery of Ad-hOC-E1 have been hampered historically by the lack of an adequate experimental animal model, because human adenoviruses replicate only in human cells. However, OC promoter activity has largely been restricted to osseous tissues with marginally detectable levels in the brain of transgenic animals, using 3.9 kb of human OC promoter construct fused to the CAT reporter. 44, 45 The safety of an adenoviral vector carrying OC promoter-driven HSV-TK gene was also recently demonstrated in a Phase I clinical trial. 46 The major side effect of high-dose vitamin D administration is hypercalcemia, which would jeopardize its clinical utility. Although the vitamin D 3 analogue Ro 25-9022, used in the present study, has not been tested at the maximum tolerated dose, when mice treated with 4 ng of Ro 25-9022 twice per week were compared with untreated mice, they showed only a mild side effect, a less than 10% body weight reduction for a period of 3 weeks. The mice recovered after the vitamin D 3 treatment was stopped, which is consistent with our previous study. 22 This minor side effect could be further overcome by using other structural analogs of 1,25(OH) 2 D 3 that have been developed, which show significant antiproliferative activity but a less calcemic effect in vivo. 47 The results of our work suggest that combination therapy with conditional replication-competent adenovirus and an antiangiogenic gene therapy targeting the VEGF axis may have clinical utility for prostate cancer treatment. Several issues remain to be addressed, some of which cannot be examined using the currently available animal models. In practice, intratumoral administration of the adenovirus in cancer patients may result in the production of neutralizing antibodies with subsequent elimination of infected cells, particularly after multiple treatments. However, additional virus-induced cytotoxic effects might prove beneficial in some instances. It has been shown that the recruitment and stimulation of tumor-specific T lymphocytes can lead, in some cases, to systemic antitumor immunity.
Experimental data from several other laboratories provided intriguing evidence that aggressive breast and prostatic carcinoma and melanoma tumors demonstrate vasculogenic mimicry, [48] [49] [50] by which tumor cells form de novo vasculogenic-like networks in vitro in the absence of endothelial cells or fibroblasts, concomitant with the expression of several vascular-associated markers including thrombin receptor, endothelin-B receptor, endoglin, TIE-2 or Flk1. 51 In addition to in vitro cell models, tumor cell-lined vasculature is detectable in clinical specimens, 52, 53 suggesting an important role for vasculogenic mimicry in the establishment, growth and metastasis of aggressive human tumors. We have observed that the ability of prostate cancer cell lines to form patterned vasculogenic-like networks in 3D Matrigel culture in vitro is associated with their tumorigenicity in vivo (Jin, unpublished data). Additional molecular studies are in progress in our laboratory to elucidate the molecular mechanism responsible for vasculogenic mimicry. Based on the expression of Flk1, one of the key vascular markers in C4-2 cells, it is tempting to speculate that the induction of tumor cell apoptosis by Ad-Flk1-Fc shown in our study may be partly attributable to blocking the formation of tumor-lined vasculature in addition to endotheliallined vasculature.
In summary, we have demonstrated that the adenovirus-mediated intratumoral transfer of an ectodomain of the Flk1 gene is an efficient means of delivering gene therapy to both vascular endothelial cells and prostate cancer cells, resulting in suppressed tumor growth via an indirect antiangiogenic mechanism and/or direct tumor cell kill. Our results showed that eliminating cancer cells with a conditional replication-competent adenovirus could improve the therapeutic effectiveness of Ad-Flk1-Fc through Ad-vector-induced oncolysis and subsequent Ad infection of tumor cells and their adjacent neovasculature. Our ''proof-of-concept'' study establishes for the first time that the adenovirus-mediated cotargeting of prostate cancer and tumor endothelium may be an effective strategy for destroying androgen-independent and metastatic human prostate tumors. Future studies are planned to improve the therapeutic effects of combination therapies for the eradication of larger sizes of prostate tumors.
